Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
84 hedge funds and large institutions have $209M invested in Adamas Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 26 closing their positions.
153% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 93 → 84 (-9)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
34% less capital invested
Capital invested by funds: $317M → $209M (-$108M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.3M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$11M |
| 3 |
BWCA
Brenner West Capital Advisors
New York
|
+$9.15M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$9.12M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.05M |
| 2 |
Renaissance Technologies
New York
|
-$4.81M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$4.01M |
| 4 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$2.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.03M |
ADMS Hedge Fund Activity: Q1 2016 in Review
84 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2016, worth a combined $209M — down 34% from $317M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ADMS and 19 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 38 added.
The largest buyer was Great Point Partners, adding an estimated $11.3M. The largest seller was Millennium Management, cutting an estimated $6.05M.
- 84 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2016, down from 93 in Q4 2015.
- Funds reported $209M of Adamas Pharmaceuticals stock for Q1 2016, down 34% quarter-over-quarter.
- 19 funds opened new Adamas Pharmaceuticals positions in Q1 2016 and 26 closed out, a net change of -7 holders.
- The largest Adamas Pharmaceuticals buyer in Q1 2016 was Great Point Partners, an estimated $11.3M added.
- The largest Adamas Pharmaceuticals seller in Q1 2016 was Millennium Management, an estimated $6.05M sold.
Based on aggregated 13F filings for Q1 2016.